흰쥐 생체시료 중 5-플루오로우라실 및 테가푸르의 안정성 = Stability of 5-FU and Tegafur in Biological Fluids of Rats

다국어 초록 (Multilingual Abstract)

5-Fluorouracil (5-FU) is an antimetabolite anticancer agent active against many types of solid tumors. Tegafur (TF), a prodrug of 5-FU, is frequently used in combination with uracil as dihydropyrimidine dehydrogenase (DPD) inhibitory fluoropyrimidine. We studied the stability of 5-FU and TF in biological fluids of rats and determined their bioavailability (BA) and excretion into bile, and urine. The drug concentrations were analyzed by an HPLC method. At room temperature, there was a 14-30% decrease in the concentration of 5-FU and TF in bile, urine, and plasma specimen at 10 and 100 μg/ml over 240 min. No significant difference was noted among the sample types or between two different concentrations of 10 and 100 μg/ml. The decrease in drug concentration was significantly less in samples kept on ice (6-12%) for both drugs. These data indicate that biological fluid samples containing 5-FU or TF in plasma, urine, or bile should be placed on ice during the sample collection. Following these storage guidelines, samples were collected after administration 50 ㎎/㎏ of each drug via i.v. or oral route. BA was 1.5 folds greater for TF (60%) than that of 5-FU (42%). Approximately 0.52 and 3.3% of the i.v. doses of 5-FU and TF was excreted into bile, respectively. Renal clearance of 5-FU was about 16% of its total body clearance. These results suggest that instability of 5-FU and TF in biological fluids should be considered in pharmacokinetic or pharmacogenomic studies.

참고문헌 (Reference)

1 "parotid saliva" j. pharm. sci. : 72-, 597-599

2 "Stability of 5-fluorouracil in whole blood and plasma" 33 : 2299-2300, 1987

3 "Rat cytochrome P-450 1A and 3A enzymes involved in bioactivation of tegafur to 5-fluorouracil and autoinduced by tegafur in liver microsomes" 29 : 794-797, 2001

4 "Pharmacokinetics of ftorafur after intravenous and oral administration" 10 : 150-153, 1983

5 "Oral uracil and Ftorafur plus leucovorin: Pharmacokinetics and toxicity in patients with metastatic cancer" 46 : 351-356, 2000

6 "Oral DPD-inhibitory fluoropyrimidine drugs" 14 : 19-23, 2000

7 "Nonlinear pharmacokinetic models for 5-fluorouracil in man:Intravenous and intraperitoneal routes" 28 : 235-246, 1980

8 "M.N. Raber and I.H. Krakoff" drug metab. dispos. : 20-, 936-940

9 "Human urinary metabolites of 1-" 3199-3201, 1979

10 "HPLC analysis of 5-FU and FdUMP in tissue and serum" 216 : 808-813, 1995

11 "First-pass metabolism of 5-fluorouracil in the perfused rat small intestine" 21 : 871-873, 1998

12 "First-pass metabolism of 5-fluorouracil in rats" 50 : 1019-1025, 1998

13 "Dose-dependent gastrointestinal absorption of 5-fluorouracil in rats in vivo" 19 : 1494-1498, 1996

14 "Determination of ftorafur and 5-fluorouracil levels in plasma and urine" 14 : 89-102, 1976

15 "Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil" 4 : 2085-2088, 1998

16 "Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouraci" 4 : 2085-2088, 1998

17 "Clinical pharmacology of 5-fluorouracil" 16 : 215-237, 1989

18 "Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics" 19 : 177-189, 2002

19 "Clinical Evaluation of ftorafur" 1821-18241976

20 "Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro" 6 : 4409-4415, 2000

21 "5-fluorouracil:mechanisms of action and clinical strategies" 3 : 330-338, 2003

22 "5-Fluorouracil prodrug:role of anabolic and catabolic pathway modulation in therapy of colorectal cancer" 1 : 839-845, 1995